Ecoza
(Oteseconazole with Flucytosine - antifungal therapy 4)Preclinical
Ecoza is one of 37 small molecule programs targeting HIV. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in HIV
#DrugCompanyPhaseTrials
1Cabenuva
GSKApproved
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tivicay
GSKPhase 3
Epivir
GGlaxo Dba Glaxosmithkline
Phase 3
Sunlenca
GileadPhase 3
Vemlidy
GileadPhase 3
Emtriva
GileadPhase 3
Biktarvy
GileadPhase 3
Priftin
SanofiPhase 2
Lamprene
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 23, 1982
SPECTAZOLE
NDA NDA018751
Oct 24, 2013
ECOZA
NDA NDA205175
Apr 26, 2022
VIVJOA
NDA NDA215888
Sources
References
- [1]
- [2]
- [3]
- [4]
- [5]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- AAlvogen Korea